Study #2024-1023
A randomized, double-blind, placebo-controlled study of LMN-201 for prevention of C. difficile infection recurrence (RePreve)
MD Anderson Study Status
Enrolling
Treatment Agent
LMN-201, Placebo
Description
This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Clostridioides Difficile Infection
Study phase:
Phase II/III
Physician name:
Pablo Okhuysen
Department:
Infectious Diseases
For general questions about clinical trials:
1-844-491-2084
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.